The physician orders ciprofloxacin 375mg IV q12h. The medication contains 37.5 mg/mL. How many mL will be administered? (Please Show All Work on Provided scrap paper, enter numerical value only. Do not enter unit of measurement).

A. "The patch will work quickly and effectively to manage your pain.": Transdermal patches have a slow onset of action, often taking 12 to 24 hours to reach therapeutic steady-state levels. Promising a "quick" result is medically inaccurate and mismanages the client's expectations for relief. Patches are designed for long-term maintenance rather than rapid acute analgesia.

B. "The patch will give you a longer duration of pain relief especially during sleep.": While true that patches provide long-acting relief, this statement does not address the client's primary concern about adequacy or previous dissatisfaction with sedation. It fails to explain the pharmacokinetic advantage of consistent dosing over intermittent oral boluses. It provides incomplete education regarding the transition.

C. "The patch has creams and oils imbedded in it to prevent friction and shearing which can lead to skin breakdown.": This is a physiological falsehood regarding the construction of transdermal delivery systems. Patches contain a drug reservoir and an adhesive, but they are not designed as skin-protective barriers against mechanical shearing. Their purpose is systemic drug delivery, not localized dermatological protection.

D. "The patch will maintain consistent levels of the drug in your blood. We may be able to supplement with another pain medication until pain control is reached.": Continuous delivery avoids the "peaks" and "troughs" associated with oral meds, which often cause excessive sedation at peak and pain at trough. Informing the client about supplemental "breakthrough" medication provides a safety net during the slow onset period of the transdermal system.

A. Administer the pain mediation around the clock if necessary: For chronic cancer pain, "around the clock" (ATC) dosing maintains a steady therapeutic plasma concentration of the analgesic. This prevents the "cycling" of pain and the difficult task of treating breakthrough pain after it has become severe. Steady-state dosing improves overall quality of life.

B. Initiate techniques to limit the amount of opioids administered: In terminal or metastatic cancer care, the priority is effective palliation and comfort rather than preventing opioid dependence or limiting dosages. Fear of addiction should not impede the administration of adequate analgesia for patients with life-limiting malignancies and severe pain.

C. Administer the analgesic promptly as soon as the client's pain becomes severe: Waiting for pain to become severe before medicating makes it much harder to achieve relief and often requires higher total doses. This "PRN" approach is less effective for chronic, persistent pain than a proactive, scheduled dosing regimen.

D. Administer medications intravenously for greater duration of the drug's effectiveness: The intravenous route actually has the shortest duration of action due to rapid distribution and elimination. For chronic pain, oral or transdermal routes are preferred as they provide a more sustained and long-lasting analgesic effect compared to IV boluses.